Last updated: February 14, 2026
Market Analysis and Price Projections for NDC 00781-2343
Overview
NDC 00781-2343 corresponds to Fosaprepitant Dimeglumine Injection, marketed as Emend Powder for Injection by Merck & Co. It is an antiemetic used to prevent nausea and vomiting in chemotherapy patients. The drug's primary indication has established a steady market, especially in oncology settings.
Current Market Landscape
| Attribute |
Data |
| Market Exclusivity |
Patent expired in the U.S. as of March 2021, opening market for generics. |
| Market Size (2022) |
Estimated at $150 million globally, driven by oncology treatments. |
| US Market Share |
Estimated at 70% of total sales, with remaining sales split among Europe and Asia. |
Key Drivers:
- Adoption in chemotherapy protocols.
- Increased cancer prevalence.
- Regulatory approvals for generic formulations.
Competitive Environment:
- Multiple generics introduced post-patent expiry.
- Major players include Teva, Sun Pharma, Aurobindo.
- Little differentiation beyond pricing due to bioequivalence.
Price Trends and Projections
| Year |
Average Price per 50 mg Vial (USD) |
Change YoY |
Sources |
| 2020 |
$200 |
- |
[1] |
| 2021 |
$180 |
-10% |
[2] |
| 2022 |
$165 |
-8.3% |
[3] |
Prices have declined following generic entry, driven by increased competition.
Future Price Scenario:
- Short-term (1-2 years): Prices stabilized around $160-$170; minimal further decline expected due to market saturation.
- Medium-term (3-5 years): Prices likely to decline marginally, reaching approximately $150-$155 driven by generic competition and price negotiations.
- Long-term (5+ years): Possible further decrease if new formulations or alternative therapies emerge; target price may lower to ~$140.
Revenue Projections
- 2023: Approximate global sales of $135 million, assuming a 10% decline from 2022.
- 2025: Estimated sales around $125 million, with market stabilization.
Cost and Margins
- Generic manufacturers can produce at lower costs, roughly $50-$70 per vial.
- Gross margins for generics range from 40-50%, depending on volume and market access.
Policy and Regulatory Influences
- US Patent Situation: Patent expired, facilitating generic entry.
- Pricing Regulations: U.S. pricing reforms may influence reimbursement policies, potentially reducing prices further.
- International Markets: Regulatory approvals and pricing controls vary; European markets generally have lower prices due to national negotiations.
Competitive Positioning and Strategic Considerations
- Brand vs. Generic: Brand remains relevant where prescribers favor original products until fully replaced.
- Pricing Strategies: Generics will continue to compete primarily on price; discounts and rebates influence actual transaction prices.
- Market Expansion: Growing acceptance in Asia could create additional revenue streams.
Key Takeaways
- The market for Fosaprepitant Dimeglumine Injection has shifted toward generic dominance post-patent expiry.
- Prices have declined steadily over the last two years, with a projection of slight decreases in the next five years.
- The global market remains sizable but highly competitive, with primary growth in emerging markets.
- Price control policies and formulary decisions will influence future revenues and profitability.
FAQs
Q1: What factors could stabilize or increase the price of Fosaprepitant Dimeglumine?
A1: Patent protections, formulation innovations, or new approvals for expanded indications could stabilize or raise prices temporarily.
Q2: How do international markets impact the overall price trend?
A2: Prices are lower in Europe and Asia due to negotiating power and regulatory policies, influencing global averages.
Q3: Will new competitors enter the market?
A3: Market saturation limits new entrants; most generic manufacturers already produce the drug.
Q4: How does the availability of generics affect the original brand's market share?
A4: Generic entry typically erodes brand sales unless the brand maintains loyalty or differentiates through additional features.
Q5: What is the outlook for biosimilar versions?
A5: Biosimilar versions are unlikely due to the small molecule nature of the drug but could influence pricing dynamics if developed for related compounds.
References
- IMS Health, 2020 data.
- MarketWatch, 2021.
- EvaluatePharma, 2022.
